Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin
about
Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.Hodgkin lymphoma transformation of chronic lymphocytic leukemia: cases report and discussion.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Merocyclophanes C and D from the Cultured Freshwater Cyanobacterium Nostoc sp. (UIC 10110).Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer GrowthNew Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.
P2860
Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Emerging Pharmacotherapy for R ...... : Focus on Brentuximab Vedotin
@ast
Emerging Pharmacotherapy for R ...... : Focus on Brentuximab Vedotin
@en
type
label
Emerging Pharmacotherapy for R ...... : Focus on Brentuximab Vedotin
@ast
Emerging Pharmacotherapy for R ...... : Focus on Brentuximab Vedotin
@en
prefLabel
Emerging Pharmacotherapy for R ...... : Focus on Brentuximab Vedotin
@ast
Emerging Pharmacotherapy for R ...... : Focus on Brentuximab Vedotin
@en
P2860
P356
P1476
Emerging Pharmacotherapy for R ...... : Focus on Brentuximab Vedotin
@en
P2093
Michelle Furtado
Simon Rule
P2860
P356
10.4137/CMO.S6637
P407
P577
2012-01-04T00:00:00Z